All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10125444" target="_blank" >RIV/00179906:_____/12:10125444 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1001/jama.2011.2002" target="_blank" >http://dx.doi.org/10.1001/jama.2011.2002</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1001/jama.2011.2002" target="_blank" >10.1001/jama.2011.2002</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial

  • Original language description

    Abstract: Context Thienopyridines are among the most widely prescribed medications, but their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 to 7 days prior to surgery to minimize bleeding. Objective To evaluate the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery. Design, Setting, and Patients Prospective, randomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopyridine awaiting CABG surgery to receive eithercangrelor or placebo after an initial open-label, dose-finding phase (n=11) conducted between January 2009 and April 2011. Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hou

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2012

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of the American Medical Association

  • ISSN

    0098-7484

  • e-ISSN

  • Volume of the periodical

    307

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    10

  • Pages from-to

    265-274

  • UT code for WoS article

    000299161200022

  • EID of the result in the Scopus database